Oct 20, 2020
By Becky Ditty, Consultant
With Centers for Medicare and Medicaid Services (CMS) now offering an add-on payment route for breakthrough designated medical devices, it is anticipated that more companies will be submitting requests to FDA for breakthrough designation status.
To qualify for breakthrough designation as defined in section 515B(b) of the FD&C Act (21 U.S.C. 360e-2(b)), the device must meet Criterion 1 (described below) as well as one of the criteria described in Criterion 2.
Devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions; and
(A) that represent breakthrough technologies
(B) for which no approved or cleared alternatives exist;
(C) that offer significant advantages over existing approved or cleared alternatives, including the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patient’s ability to manage their own are (such as through self-directed personal assistance), or establish long-term clinical efficiencies; or
(D) the availability of which is in the best interest of patients.
Additionally, the designation must be granted prior to submitting a marketing application for the device.
A Designation Request for Breakthrough Devices Q-Submission should include:
The main benefit for being designated a breakthrough device is access to the sprint process, which is intended to be highly interactive between FDA and the sponsor.
For additional details, including timelines associated with a breakthrough device designation and when a device would benefit from the designation, refer to our in-depth article and to FDA guidance “Breakthrough Devices Program”.
Food and Drug Administration (FDA). (2020). Breakthrough Devices Program Guidance for Industry and Food and Drug Administration Staff. Retrieved from source.
Fill out the form below to submit your commentary